

POSTER PRESENTATION

Open Access

cGMP and PKGI are required for vascular BMP signaling

Raphaela Schwappacher*, Thuan Diep, Gerry Boss, Renate Pilz

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Halle, Germany. 24-26 June 2011

Background

Maintenance of vascular homeostasis depends on phenotypic switching of vascular smooth muscle cells (VSMCs) during development, vascular injury repair, and disease. In healthy blood vessels, VSMCs exhibit a differentiated, 'contractile' phenotype, but in diseased vascular tissue or after vascular injury, they de-differentiate into a 'synthetic' state, characterized by decreased smooth muscle (SM)-specific gene expression and increased proliferation and motility [1].

Results

Although still controversial, a large number of studies indicate that the NO/cGMP/PKGI pathway inhibits proliferation and de-differentiation of VSMCs. Subcultured primary VSMCs undergo de-differentiation to a 'synthetic' phenotype with both reduced SM-specific gene expression and loss of PKGI expression. A more 'contractile' phenotype can be regained by restoring PKGI [2]. PKGI stimulates SM-specific gene expression through regulation of the cystein-rich LIM only protein CRP4 that cooperates with SRF-containing transcription complexes [3]. But the mechanism how cGMP/PKGI regulates SM-specific phenotype is incompletely understood. In C2C12 myoblasts, PKGI phosphorylates the BMP type II receptor (BMPRII); in response to BMP-2, PKGI dissociates from the receptor, associates with the activated Smad1/4 complex, translocates to the nucleus, and forms a complex with Smads and the general transcription factor TFII-I to collaboratively activate transcription [4]. In the vascular system, BMP signaling inhibits proliferation and migration of VSMCs, and upregulates SM-specific genes, through Smad-dependent

[5-8] and/or Smad-independent pathways [9-11]. Interestingly, heterozygous germline mutations within BMPRII can cause pulmonary arterial hypertension (PAH), a disease characterized by thickening of pulmonary arteries due to abnormal proliferation, migration, and/or apoptosis of VSMCs and endothelial cells [12]. Considering these data we hypothesize that PKGI promotes the differentiated 'contractile' phenotype of VSMCs at least in part through enhancing vascular BMP/Smad signaling. Indeed we found that cGMP/PKGI promoted Smad1/5 activation and BMP target gene expression in VSMCs and SM precursor cells. Pharmacological or siRNA-mediated inhibition of the NO/cGMP/PKGI pathway not only suppressed BMP-induced upregulation of SM-specific gene transcription, but also abrogated the anti-proliferative and anti-migratory effects of BMP on VSMCs. Furthermore preliminary data suggest that Smad crosstalk with other transcriptional regulators is involved.

Conclusion

Our data imply that within the vasculature, PKGI is a critical regulator of the VSMC differentiation-promoting effects of BMP. The integration of cGMP/PKGI pathway into BMP/Smad signaling in the vascular system might provide new insight into the mechanisms of vascular remodeling in diseases such as atherosclerosis, vascular restenosis and pulmonary hypertension.

Published: 1 August 2011

References

1. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol Rev* 2004, **84**:767-801.
2. Lincoln TM, Wu X, Sellak H, Dey N, Choi CS: Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. *Front Biosci* 2006, **11**:356-367.

* Correspondence: rschwappacher@ucsd.edu
Department of Medicine, University of California at San Diego, San Diego, CA 92093, USA

3. Zhang T, Zhuang S, Casteel DE, Looney DJ, Boss GR, Pilz RB: **A cysteine-rich LIM-only protein mediates regulation of smooth muscle-specific gene expression by cGMP-dependent protein kinase.** *J Biol Chem* 2007, **282**:33367-33380.
4. Schwappacher R, Weiske J, Heining E, Ezerski V, Marom B, Henis YI, Huber O, Knaus P: **Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.** *EMBO J* 2009, **28**:1537-1550.
5. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A: **Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.** *J Biol Chem* 2007, **282**:37244-37255.
6. Chan MC, Hilyard AC, Wu C, Davis BN, Hill NS, Lal A, Lieberman J, Lagna G, Hata A: **Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression.** *Embo J* 2010, **29**:559-573.
7. Davis BN, Hilyard AC, Lagna G, Hata A: **SMAD proteins control DROSHA-mediated microRNA maturation.** *Nature* 2008, **454**:56-61.
8. Chan MC, Weisman AS, Kang H, Nguyen PH, Hickman T, Mecker SV, Hill NS, Lagna G, Hata A: **The amiloride derivative phenamil attenuates pulmonary vascular remodeling by activating NFAT and the bone morphogenetic protein signaling pathway.** *Mol Cell Biol* 2011, **31**:517-530.
9. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M: **An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.** *J Clin Invest* 2008, **118**:1846-1857.
10. Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, Grimminger F, Schermuly RT, Morrell NW: **Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.** *Circ Res* 2010, **107**:252-262.
11. Perez VA, Ali Z, Alastalo TP, Ikeno F, Sawada H, Lai YJ, Kleisli T, Spiekerkoetter E, Qu X, Rubinos LH, Ashley E, Amieva M, Dedhar S, Rabinovitch M: **BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways.** *J Cell Biol* 2011, **192**:171-188.
12. Morrell NW: **Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension.** *Adv Exp Med Biol* 2010, **661**:251-264.

doi:10.1186/1471-2210-11-S1-P65

Cite this article as: Schwappacher *et al.*: cGMP and PKGI are required for vascular BMP signaling. *BMC Pharmacology* 2011 **11**(Suppl 1):P65.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

